Eli Lilly (NYSE:LLY) announced Wednesday that an executive search is underway to find an internal or external replacement for ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association International ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer’s disease in the ...

The Trump administration's ever-changing tariffs and Most Favored Nation drug pricing are part of a blizzard of unclear, ...

The stock of Eli Lilly has a consensus Strong Buy rating among 22 Wall Street analysts. That rating is based on 17 Buy and ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...